Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience
- 1 June 2019
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 19 (6), 390-395
- https://doi.org/10.1016/j.clml.2019.03.003
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (T32 HL007093)
- National Heart, Lung, and Blood Institute
- Histogenetics and the Seattle Translational Tumor Research Fund
This publication has 32 references indexed in Scilit:
- Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008Blood, 2013
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancyBone Marrow Transplantation, 2011
- Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapyLeukemia, 2010
- Therapy-related myeloid neoplasmsHaematologica, 2009
- Therapy-Related Myeloid LeukemiaSeminars in Oncology, 2008
- A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancersCancer Causes & Control, 2007
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTBlood, 2005
- Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemiaAmerican Journal of Hematology, 2005
- Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011Journal of Clinical Oncology, 2002